As the P.R. machine kicks into gear to support the launch of Spravato/Esketamine, the first FDA approved Ketamine-derived treatment, Kevin Nicholson (President, CEO of Ketamine Wellness Centers) digs into the details that tend to receive less attention.One thing that raised the eyebrows of everybody on the clinical team here at KWC relates to the recommended dosing of Spravato.

On this episode, we discuss:

- What is the recommended dosing during the stabilization and maintenance treatment phases?

- Is the dosing variable from patient to patient or fixed?

- What are the implications of utilizing a non-variable prescription for dosing?

www.ketaminewellnesscenters.com/category/podcast/